Sensitive and Specific Detection of the Non-Human Sialic Acid N-Glycolylneuraminic Acid In Human Tissues and Biotherapeutic Products

Background Humans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), but can metabolically incorporate it from dietary sources (particularly red meat and milk) into glycoproteins and glycolipids of human tumors, fetuses and some normal tissues. Metabolic incorporation of Neu5Gc from animal-derived cells and medium components also results in variable contamination of molecules and cells intended for human therapies. These Neu5Gc-incorporation phenomena are practically significant, because normal humans can have high levels of circulating anti-Neu5Gc antibodies. Thus, there is need for the sensitive and specific detection of Neu5Gc in human tissues and biotherapeutic products. Unlike monoclonal antibodies that recognize Neu5Gc only in the context of underlying structures, chicken immunoglobulin Y (IgY) polyclonal antibodies can recognize Neu5Gc in broader contexts. However, prior preparations of such antibodies (including our own) suffered from some non-specificity, as well as some cross-reactivity with the human sialic acid N-acetylneuraminic acid (Neu5Ac). Methodology/Principal Findings We have developed a novel affinity method utilizing sequential columns of immobilized human and chimpanzee serum sialoglycoproteins, followed by specific elution from the latter column by free Neu5Gc. The resulting mono-specific antibody shows no staining in tissues or cells from mice with a human-like defect in Neu5Gc production. It allows sensitive and specific detection of Neu5Gc in all underlying glycan structural contexts studied, and is applicable to immunohistochemical, enzyme-linked immunosorbent assay (ELISA), Western blot and flow cytometry analyses. Non-immune chicken IgY is used as a reliable negative control. We show that these approaches allow sensitive detection of Neu5Gc in human tissue samples and in some biotherapeutic products, and finally show an example of how Neu5Gc might be eliminated from such products, by using a human cell line grown under defined conditions. Conclusions We report a reliable antibody-based method for highly sensitive and specific detection of the non-human sialic acid Neu5Gc in human tissues and biotherapeutic products that has not been previously described.

[1]  A. Varki,et al.  Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression , 2008, Proceedings of the National Academy of Sciences.

[2]  David F. Smith,et al.  Incorporation of a non-human glycan mediates human susceptibility to a bacterial toxin , 2008, Nature.

[3]  A. Varki,et al.  Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. , 2008, Glycobiology.

[4]  A. Varki.  Multiple changes in sialic acid biology during human evolution , 2008, Glycoconjugate Journal.

[5]  G. Gil,et al.  Structural analysis of α‐Gal and new non‐Gal carbohydrate epitopes from specific pathogen‐free miniature pig kidney , 2008, Proteomics.

[6]  S. Misbah,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[7]  Quynh-Thu Le,et al.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.

[8]  R. Dwek,et al.  Monosialylated biantennary N-glycoforms containing GalNAc-GlcNAc antennae predominate when human EPO is expressed in goat milk. , 2008, Archives of biochemistry and biophysics.

[9]  D. Opstelten,et al.  PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins , 2008 .

[10]  Yukari Nakajima,et al.  Study on the quality control of cell therapy products. Determination of N-glycolylneuraminic acid incorporated into human cells by nano-flow liquid chromatography/Fourier transformation ion cyclotron mass spectrometry. , 2007, Journal of Chromatography A.

[11]  A. Varki,et al.  Efficient chemoenzymatic synthesis of biotinylated human serum albumin-sialoglycoside conjugates containing O-acetylated sialic acids. , 2007, Organic & biomolecular chemistry.

[12]  A. Varki,et al.  N-Glycolylneuraminic Acid Deficiency in Mice: Implications for Human Biology and Evolution , 2007, Molecular and Cellular Biology.

[13]  J. Brisson,et al.  Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes. , 2007, Biochemistry.

[14]  J. Laine,et al.  N‐Glycolylneuraminic Acid Xenoantigen Contamination of Human Embryonic and Mesenchymal Stem Cells Is Substantially Reversible , 2007, Stem cells.

[15]  V. Koliatsos,et al.  Nonhuman sialic acid Neu5Gc is very low in human embryonic stem cell-derived neural precursors differentiated with B27/N2 and noggin: Implications for transplantation , 2006, Experimental Neurology.

[16]  Guillermo Sapiro,et al.  Shapes of antibody binding sites: qualitative and quantitative analyses based on a geomorphic classification scheme. , 2006, The Journal of organic chemistry.

[17]  F. Gage,et al.  Human embryonic stem cells express an immunogenic nonhuman sialic acid , 2005, Nature Medicine.

[18]  A. Varki,et al.  Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Zhu,et al.  Anti‐N‐glycolylneuraminic acid antibodies identified in healthy human serum , 2002, Xenotransplantation.

[20]  A. Varki.  Loss of N‐glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution , 2002, American journal of physical anthropology.

[21]  Y. Malykh,et al.  N-Glycolylneuraminic acid in human tumours. , 2001, Biochimie.

[22]  T. Raju,et al.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.

[23]  A. van der Eb,et al.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.

[24]  M. Naiki,et al.  Potential use of specific human and chicken antibodies for detection of Hanganutziu-Deicher antigen(s) in sera of cancer patients. , 1994, Japanese journal of medical science & biology.

[25]  T. Saida,et al.  Analysis of the Expression of Hanganutziu‐Deicher (HD) Antigen in Human Malignant Melanoma , 1992, The Journal of dermatology.

[26]  J. Kamerling,et al.  A strategy for the mapping of N-glycans by high-pH anion-exchange chromatography with pulsed amperometric detection. , 1992, Analytical biochemistry.

[27]  D. Bundle,et al.  Thermodynamics of oligosaccharide binding to a monoclonal antibody specific for a Salmonella O-antigen point to hydrophobic interactions in the binding site. , 1992, The Journal of biological chemistry.

[28]  M. Naiki,et al.  Use of biotinylated antibody for the assay of Hanganutziu-Deicher antibodies and antigens in fluids and tissues from cancer patients. , 1989, The Japanese journal of veterinary research.

[29]  M. Naiki,et al.  Detection of glycoproteins as tumor-associated Hanganutziu-Deicher antigen in human gastric cancer cell line, NUGC4. , 1989, Biochemical and biophysical research communications.

[30]  R. Kannagi,et al.  Generation of two murine monoclonal antibodies that can discriminate N-glycolyl and N-acetyl neuraminic acid residues of GM2 gangliosides. , 1988, Cancer research.

[31]  E. Kabat,et al.  Model-building study of the combining sites of two antibodies to alpha (1----6)dextran. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Higashi,et al.  Detection of Gangliosides as N‐Glycolylneuraminic Acid‐specific Tumor‐associated Hanganutziu‐Deicher Antigen in Human Retinoblastoma Cells , 1988, Japanese journal of cancer research : Gann.

[33]  Y. Hirabayashi,et al.  Specific expression of unusual GM2 ganglioside with Hanganutziu-Deicher antigen activity on human colon cancers. , 1987, Japanese journal of cancer research : Gann.

[34]  Y. Hirabayashi,et al.  Characterization of N-glycolylneuraminic acid-containing gangliosides as tumor-associated Hanganutziu-Deicher antigen in human colon cancer. , 1985, Cancer research.

[35]  K. Ikuta,et al.  Tumor-associated expression of glycosphingolipid Hanganutziu-Deicher antigen in human cancers. , 1984, Gan.

[36]  Y. Ohashi,et al.  Hanganutziu-Deicher heterophile antigen in human retinoblastoma cells. , 1983, American journal of ophthalmology.

[37]  M. Naiki,et al.  Antigen of "serum sickness" type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acid. , 1977, Biochemical and biophysical research communications.

[38]  E. Brown,et al.  Approaches to the release of a master cell bank of PER.C6 cells; a novel cell substrate for the manufacture of human vaccines. , 2006, Developments in biologicals.

[39]  T. Saida,et al.  Immunohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma , 2004, Archives of Dermatological Research.

[40]  T. Logtenberg,et al.  High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6 , 2003, Biotechnology progress.

[41]  W. W. Nichols,et al.  Propagation of Adenoviral Vectors: Use of PER. C6 Cells , 2002 .

[42]  J. Rohrer,et al.  Analysis of the N-acetylneuraminic acid and N-glycolylneuraminic acid contents of glycoproteins by high-pH anion-exchange chromatography with pulsed amperometric detection. , 1998, Glycobiology.

[43]  M. Naiki,et al.  Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. , 1995, Journal of biochemistry.

[44]  K. Furukawa,et al.  Monoclonal antibody R24 distinguishes between different N-acetyl- and N-glycolylneuraminic acid derivatives of ganglioside GD3. , 1988, Archives of biochemistry and biophysics.

[45]  Y. Hirabayashi,et al.  N-Glycolylneuraminic Acid-Containing Gangliosides as a Tumor Associated Antigen in Human: Expression of Hanganutziu-Deicher Antigen Active Gangliosides on Human Colon Carcinoma and Melanoma Tissues , 1988 .

[46]  Y. Ohkura,et al.  Highly sensitive determination of N-acetyl- and N-glycolylneuraminic acids in human serum and urine and rat serum by reversed-phase liquid chromatography with fluorescence detection. , 1986, Journal of chromatography.

[47]  H. Higashi.  Tumor-associate expressionof glycosphingolipid Hanganutziu-Deicher antigen in human cacers , 1984 .